Our top pick for
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our opinions or reviews. Learn how we make money.
Viking Therapeutics, Inc is a biotechnology business based in the US. Viking Therapeutics shares (VKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Viking Therapeutics employs 18 staff and has a market cap (total outstanding shares value) of USD$416.9 million.
Since the stock market crash in March caused by coronavirus, Viking Therapeutics's share price has had significant negative movement.
Its last market close was USD$6.6, which is 4.76% down on its pre-crash value of USD$6.93 and 102.45% up on the lowest point reached during the March crash when the shares fell as low as USD$3.26.
If you had bought USD$1,000 worth of Viking Therapeutics shares at the start of February 2020, those shares would have been worth USD$630.83 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$1,028.02.
|Latest market close||USD$6.6|
|52-week range||USD$3.26 - USD$8.87|
|50-day moving average||USD$7.1232|
|200-day moving average||USD$6.4848|
|Wall St. target price||USD$19.43|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.353|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-09-11)||15.18%|
|1 month (2020-08-18)||-14.62%|
|3 months (2020-06-18)||-12.23%|
|6 months (2020-03-18)||70.54%|
|1 year (2019-09-18)||-8.21%|
|2 years (2018-09-18)||-66.08%|
|3 years (2017-09-18)||459.32%|
|5 years (2015-09-18)||14.19%|
|Gross profit TTM||USD$0|
|Return on assets TTM||-8.37%|
|Return on equity TTM||-11.79%|
|Market capitalisation||USD$416.9 million|
TTM: trailing 12 months
There are currently 11.9 million Viking Therapeutics shares held short by investors – that's known as Viking Therapeutics's "short interest". This figure is 8.5% up from 11.0 million last month.
There are a few different ways that this level of interest in shorting Viking Therapeutics shares can be evaluated.
Viking Therapeutics's "short interest ratio" (SIR) is the quantity of Viking Therapeutics shares currently shorted divided by the average quantity of Viking Therapeutics shares traded daily (recently around 1.6 million). Viking Therapeutics's SIR currently stands at 7.36. In other words for every 100,000 Viking Therapeutics shares traded daily on the market, roughly 7360 shares are currently held short.
However Viking Therapeutics's short interest can also be evaluated against the total number of Viking Therapeutics shares, or, against the total number of tradable Viking Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viking Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Viking Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.1549% of the tradable shares (for every 100,000 tradable Viking Therapeutics shares, roughly 155 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Viking Therapeutics.
Find out more about how you can short Viking Therapeutics stock.
We're not expecting Viking Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Viking Therapeutics's shares have ranged in value from as little as $3.26 up to $8.87. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viking Therapeutics's is 1.9916. This would suggest that Viking Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.